Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Transdermal Patch Used for Delivery of HIV Drugs

October 26, 2011 5:57 am | News | Comments

An innovative delivery method for human immunodeficiency virus (HIV) medications has been developed through use of a transdermal patch, the first of its kind to treat HIV.

TOPICS:

S*Bio to Begin A Phase 3 Trial of Pacritinib

October 26, 2011 5:52 am | News | Comments

S*BIO Pte Ltd announced plans to initiate a global Phase 3 clinical program of its JAK2 inhibitor pacritinib, to further demonstrate its activity and tolerability for the treatment of myelofibrosis.

TOPICS:

FDA Approves Onfi for Lennox-Gastaut Seizures

October 26, 2011 5:48 am | News | Comments

The U.S. Food and Drug Administration approved Onfi tablets for use as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in adults and children 2 years of age and older.

TOPICS:
Advertisement

Obesity Limits Vaccine Efficacy

October 26, 2011 5:45 am | News | Comments

People carrying extra pounds may need extra protection from influenza. New research shows that obesity may make annual flu shots less effective.

TOPICS:

Merck Income Up 7.5%

October 26, 2011 5:39 am | News | Comments

Pharmaceutical and biotech equipment company Merck said its net income rose 7.5% to $315 million in the third quarter as sales increased for key drugs.

TOPICS:

Lilly Withdraws Xigris Worldwide

October 26, 2011 5:35 am | by Tom Murphy | News | Comments

Drugmaker Eli Lilly and Co. is withdrawing the severe sepsis treatment Xigris from all markets because a recently concluded study showed that it is no longer effective.

TOPICS:

Medtronic Catheter Raises Safety Concerns

October 25, 2011 9:12 am | News | Comments

Federal health regulators say an experimental catheter from Medtronic Inc. that uses extreme heat to correct irregular heartbeats caused safety side effects in nearly one-fifth of patients treated, far exceeding the study's safety goal.

TOPICS:

Cubist Buying Adolor for $190M

October 25, 2011 8:29 am | News | Comments

Cubist Pharmaceuticals, Inc. and Adolor Corporation announced that they have signed a definitive agreement under which Cubist will acquire all of the outstanding shares of Adolor for $4.25 per share in cash, or approximately $190 million.

TOPICS:
Advertisement

ImmunoGen Starts SAR3419 Phase 2 Testing

October 25, 2011 8:25 am | News | Comments

ImmunoGen, Inc. announced that its non-Hodgkin’s lymphoma treatment SAR3419 has started Phase 2 testing. SAR3419 was created by ImmunoGen and licensed to Sanofi preclinically as part of a broader collaboration.

TOPICS:

Circadian Rhythm Linked to Skin Cancer

October 25, 2011 8:20 am | News | Comments

When you’re hit with that afternoon energy lull, don’t head outside to find some sunlight to brighten your day. The same circadian rhythm that saps your afternoon energy also appears to slow down some important cellular healing mechanisms.

TOPICS:

Two Possible Treatments for Bipolar Disorder Found

October 25, 2011 8:16 am | News | Comments

Researchers investigating the genetic causes of bipolar disorder have identified two new drugs, one of which has already been found safe in clinical trials, that may be effective in treating the disorder.

TOPICS:

Sildenafil May Benefit Children with PAH

October 25, 2011 8:10 am | News | Comments

Sildenafil is currently approved for adult pulmonary arterial hypertension; however, new research shows the drug may also provide significant benefits for children with PAH, helping to improve both oxygen delivery and exercise capacity.

TOPICS:

Possible Risk of Raised IOP with Lucentis

October 25, 2011 8:07 am | News | Comments

Two major drug trials concluded there was little risk from a drug aimed at age-related macular degeneration. Yet an ophthalmologist began to note something concerning in some of her patients: an increase in pressure inside the eye.

TOPICS:

Tube Label Sets

October 25, 2011 6:23 am | Product Releases | Comments

CILS-9100 cap and tube label sets consist of multiple CILS label shapes and sizes on a single roll/letter size sheet allowing variable data printing (batch numbers, barcodes) inlab, straight from your standard laser or thermal transfer printer.

TOPICS:

Primer Digestion

October 25, 2011 6:08 am | Drug Discovery & Development | Product Releases | Comments

GE Healthcare’s ExoStar kit supports researchers by providing a high performance and cost effective product for the enzymatic removal of unincorporated primers and nucleotides from PCR and sequencing reactions.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading